Tanios S. Bekaii-Saab, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for early- and intermediate-stage hepatocellular carcinoma.
Onvansertib Exhibits Encouraging Responses in RAS-Mutant Metastatic CRC
Phase 2 CRDF-004 results revealed that the addition of onvansertib to chemotherapy/bevacizumab was well tolerated, with no unexpected toxicities observed.
Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis
Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.
EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET
Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Perioperative Chemo Improves Survival, Control in Esophageal Cancer
Patients with nonmetastatic esophageal cancer who received FLOT chemotherapy achieved a 3-year OS rate of 61.1% in an analysis of the phase 3 ESOPEC trial.
Transarterial Chemoembolization Regimen Shows PFS Improvement in HCC
Transarterial chemoembolization plus sorafenib did not significantly improve overall survival in advanced hepatocellular carcinoma vs sorafenib alone.